Table 4.
Sclerostin Versus Lipids (ALSPAC/LURIC)
| LURIC (N = 2054) | ALSPAC (N = 3015) | |||||
|---|---|---|---|---|---|---|
| Exposure | Outcome | Model | β (95% CI) | p | β (95% CI) | p |
| Sclerostin | Triglycerides (log) | 1 | 0.03 (−0.01, 0.07) | 0.173 | 0.04 (0.01, 0.08) | 0.024 |
| Sclerostin | Triglycerides (log) | 2 | 0.05 (0.00, 0.09) | 0.038 | 0.02 (−0.02, 0.05) | 0.330 |
| Sclerostin | LDL | 1 | −0.05 (−0.09, –0.01) | 0.021 | 0.05 (0.01, 0.09) | 0.007 |
| Sclerostin | LDL | 2 | −0.02 (−0.07, 0.02) | 0.337 | 0.00 (−0.03, 0.04) | 0.877 |
| Sclerostin | HDL | 1 | −0.11 (−0.15, –0.07) | <0.001 | −0.01 (−0.05, 0.02) | 0.513 |
| Sclerostin | HDL | 2 | −0.08 (−0.12, –0.04) | <0.001 | −0.03 (−0.07, 0.00) | 0.057 |
| Sclerostin | Apolipoprotein A‐I | 1 | −0.11 (−0.15, −0.07) | <0.001 | 0.00 (−0.04, 0.03) | 0.935 |
| Sclerostin | Apolipoprotein A‐I | 2 | ‐0.07 (−0.11, –0.02) | 0.002 | −0.04 (−0.07, 0.00) | 0.026 |
| Sclerostin | Apolipoprotein B | 1 | −0.01 (−0.05, 0.03) | 0.665 | 0.06 (0.02, 0.09) | 0.002 |
| Sclerostin | Apolipoprotein B | 2 | 0.01 (−0.03, 0.06) | 0.525 | 0.01 (−0.02, 0.05) | 0.464 |
| Sclerostin | Lipoprotein(a) (log) | 1 | −0.03 (−0.07, 0.02) a | 0.233 | ||
| Sclerostin | Lipoprotein(a) (log) | 2 | −0.02 (−0.06, 0.03) a | 0.432 | ||
LURIC = Ludwigshafen Risk and Cardiovascular Health; ALSPAC = Avon Longitudinal Study of Parents and Children; CI = confidence interval.
Table shows results of linear regression analysis. Results are SD change in outcome per SD increase in sclerostin, 95% CI, and p value. Model 1: unadjusted; model 2: adjusted for age and ethnic group (ALSPAC) and sex (LURIC), body mass index, smoking, and social deprivation.
a
Based on n = 1927.